On October 1, 2026, Celcuity Inc. expanded its Board of Directors from eight to nine members and appointed David W. Gryska as a new independent director effective immediately. Mr. Gryska will serve through the 2027 Annual Meeting and has been assigned to the Audit and Compensation Committees. His compensation includes a pro-rated annual cash retainer of $70,000 and an equity award valued at $100,000, with an initial grant of 893 restricted stock units vesting upon the earlier of the 2027 Annual Meeting or April 30, 2027. Celcuity Inc. is a biotechnology company focused on developing and commercializing targeted therapies for solid tumor indications.
